Astarazenka, one of the pharmaceutical companies that has succeeded in producing a vaccine for Covid-19, is collaborating with an artificial ielligence company based in the United States of America called Absci to find cancer aibodies. These two companies are both active in the pharmaceutical field and have a history of useful products in this field.
According to Hoshio, AstraZeneca will invest up to 247 million dollars in Absci, which according to the analysis was the largest amou of trading investme in artificial ielligence in 2023. This issue is considered an importa poi considering the decrease in the amou of investmes on artificial ielligence since 2019 due to the maturity of the market and shows the importance of this project for both companies. The goal of this collaboration is to create a zero-shot generative artificial ielligence that will help experts create new therapeutic aibodies for cancer. AstraZeneca Company has not yet specified the type or types of cancer under study, and detailed information about this issue is not available.
Absci is one of the active companies in the field of artificial ielligence, which currely participates in 17 active projects. The company is one of the pioneers of generative artificial ielligence focused on health care, whose laboratory in New York operates in the field of comparison of millions of protein samples with the aim of aibody discovery. This new technology is very promising for the future treatme of rare diseases; Because artificial ielligence helps to reduce the costs of this process and save time, and in this way brings the possibility of drug tests that no company would be willing to do without artificial ielligence due to the lack of affordability. Absci claims on its website that AI can screen billions of cells every week and have a huge impact on the research process. The company also signed a deal earlier this year with bioinformatics company M2GEN to develop aibodies.
Astarazenka, one of the pharmaceutical companies that has succeeded in producing a vaccine for Covid-19, is collaborating with an artificial ielligence company based in the United States of America called Absci to find cancer aibodies. These two companies are both active in the pharmaceutical field and have a history of useful products in this field.
According to Hoshio, AstraZeneca will invest up to 247 million dollars in Absci, which according to the analysis was the largest amou of trading investme in artificial ielligence in 2023. This issue is considered an importa poi considering the decrease in the amou of investmes in artificial ielligence since 2019 due to the maturity of the market and shows the importance of this project for both companies. The goal of this collaboration is to create a zero-shot generative artificial ielligence that will help experts create new therapeutic aibodies for cancer. AstraZeneca Company has not yet specified the type or types of cancer under study, and detailed information about this issue is not available.
Absci is one of the active companies in the field of artificial ielligence, which currely participates in 17 active projects. The company is one of the pioneers of generative artificial ielligence focused on health care, whose laboratory in New York operates in the field of comparison of millions of protein samples with the aim of aibody discovery. This new technology is very promising for the future treatme of rare diseases; Because artificial ielligence helps to reduce the costs of this process and save time, and in this way brings the possibility of drug tests that no company would be willing to do without artificial ielligence due to the lack of affordability. Absci claims on its website that AI can screen billions of cells every week and have a huge impact on the research process. The company also signed a deal earlier this year with bioinformatics company M2GEN to develop aibodies.
